Increased expression of transcription factor TFAP2α correlates with chemosensitivity in advanced bladder cancer

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Nordentoft, Iver ^a   Dyrskjøt, Lars ^a   Bødker, Julie S ^a   Wild, Peter J ^b   Hartmann, Arndt ^c   Bertz, Simone ^c   Lehmann, Jan ^d   Ørntoft, Torben F ^a   Birkenkamp Demtroder, Karin ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d Urology Practice Prüner Gang   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE; PROTEIN P53; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR AP 2ALPHA; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; ISOPROTEIN; TFAP2A PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER STAGING; CANCER SURVIVAL; CELL DEATH; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; OVERALL SURVIVAL; PREDICTION; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; ANIMAL; BLADDER TUMOR; CARCINOMA; CELL STRAIN COS1; CERCOPITHECUS; DRUG EFFECT; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; METABOLISM; MORTALITY; PATHOPHYSIOLOGY; SURVIVAL; TUMOR CELL LINE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; CERCOPITHECUS AETHIOPS; CISPLATIN; COS CELLS; DEOXYCYTIDINE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; NEOPLASM STAGING; PROTEIN ISOFORMS; SURVIVAL ANALYSIS; TRANSCRIPTION FACTOR AP-2; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 79953897139     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-135     Document Type: Article

References (36)

1. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009, 374:239-249. 10.1016/S0140-6736(09)60491-8, 19520422.
2. Vaishampayan U. Systemic therapy of advanced urothelial cancer. Curr Treat Options Oncol 2009, 10:256-266. 10.1007/s11864-009-0101-9, 19408129.
3. Von Der MH, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005, 23:4602-4608. 10.1200/JCO.2005.07.757, 16034041.
4. Von Der MH, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000, 18:3068-3077.
5. Als AB, Dyrskjot L, Von Der MH, Koed K, Mansilla F, Toldbod HE, et al. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res 2007, 13:4407-4414. 10.1158/1078-0432.CCR-07-0109, 17671123.
6. Eckert D, Buhl S, Weber S, Jager R, Schorle H. The AP-2 family of transcription factors. Genome Biol 2005, 6:246. 10.1186/gb-2005-6-13-246, 1414101, 16420676.
7. Pellikainen JM, Kosma VM. Activator protein-2 in carcinogenesis with a special reference to breast cancer--a mini review. Int J Cancer 2007, 120:2061-2067. 10.1002/ijc.22648, 17330235.
8. Brewer S, Williams T. Loss of AP-2alpha impacts multiple aspects of ventral body wall development and closure. Dev Biol 2004, 267:399-417. 10.1016/j.ydbio.2003.11.021, 15013802.
9. Piao Z, Lee KS, Kim H, Perucho M, Malkhosyan S. Identification of novel deletion regions on chromosome arms 2q and 6p in breast carcinomas by amplotype analysis. Genes Chromosomes Cancer 2001, 30:113-122. 10.1002/1098-2264(2000)9999:9999<::AID-GCC1069>3.0.CO;2-6, 11135428.
10. Berger AJ, Davis DW, Tellez C, Prieto VG, Gershenwald JE, Johnson MM, et al. Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction. Cancer Res 2005, 65:11185-11192. 10.1158/0008-5472.CAN-05-2300, 16322269.
11. Ropponen KM, Kellokoski JK, Pirinen RT, Moisio KI, Eskelinen MJ, Alhava EM, et al. Expression of transcription factor AP-2 in colorectal adenomas and adenocarcinomas; comparison of immunohistochemistry and in situ hybridisation. J Clin Pathol 2001, 54:533-538. 10.1136/jcp.54.7.533, 1731475, 11429425.
12. Pellikainen J, Naukkarinen A, Ropponen K, Rummukainen J, Kataja V, Kellokoski J, et al. Expression of HER2 and its association with AP-2 in breast cancer. Eur J Cancer 2004, 40:1485-1495. 10.1016/j.ejca.2004.02.020, 15196531.
13. Anttila MA, Kellokoski JK, Moisio KI, Mitchell PJ, Saarikoski S, Syrjanen K, et al. Expression of transcription factor AP-2alpha predicts survival in epithelial ovarian cancer. Br J Cancer 2000, 82:1974-1983. 10.1054/bjoc.2000.1146, 2363243, 10864206.
14. Heimberger AB, McGary EC, Suki D, Ruiz M, Wang H, Fuller GN, et al. Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas. Clin Cancer Res 2005, 11:267-272. 10.1158/1078-0432.CCR-04-1737, 15671555.
15. Lipponen P, Aaltomaa S, Kellokoski J, Ala-Opas M, Kosma V. Expression of activator protein 2 in prostate cancer is related to tumor differentiation and cell proliferation. Eur Urol 2000, 37:573-578. 10.1159/000020195, 10765096.
16. Gee JM, Robertson JF, Ellis IO, Nicholson RI, Hurst HC. Immunohistochemical analysis reveals a tumour suppressor-like role for the transcription factor AP-2 in invasive breast cancer. J Pathol 1999, 189:514-520. 10.1002/(SICI)1096-9896(199912)189:4<514::AID-PATH463>3.0.CO;2-9, 10629551.
17. Bar-Eli M. Gene regulation in melanoma progression by the AP-2 transcription factor. Pigment Cell Res 2001, 14:78-85. 10.1034/j.1600-0749.2001.140202.x, 11310795.
18. Lehmann J, Retz M, Wiemers C, Beck J, Thuroff J, Weining C, et al. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol 2005, 23:4963-4974. 10.1200/JCO.2005.11.094, 15939920.
19. Hoffmann AC, Wild P, Leicht C, Bertz S, Danenberg KD, Danenberg PV, et al. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia 2010, 12:628-636. 2915407, 20689757.
20. Lottner C, Schwarz S, Diermeier S, Hartmann A, Knuechel R, Hofstaedter F, et al. Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer. J Pathol 2005, 205:577-584. 10.1002/path.1742, 15732132.
21. Andersen CL, Jensen JL, Orntoft TF. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 2004, 64:5245-5250. 10.1158/0008-5472.CAN-04-0496, 15289330.
22. Birkenkamp-Demtroder K, Wagner L, Brandt SF, Bording AL, Gartner W, Scherubl H, et al. Secretagogin is a novel marker for neuroendocrine differentiation. Neuroendocrinology 2005, 82:121-138. 10.1159/000091207, 16449819.
23. McPherson LA, Loktev AV, Weigel RJ. Tumor suppressor activity of AP2alpha mediated through a direct interaction with p53. J Biol Chem 2002, 277:45028-45033. 10.1074/jbc.M208924200, 12226108.
24. Karjalainen JM, Kellokoski JK, Eskelinen MJ, Alhava EM, Kosma VM. Downregulation of transcription factor AP-2 predicts poor survival in stage I cutaneous malignant melanoma. J Clin Oncol 1998, 16:3584-3591.
25. Pellikainen J, Naukkarinen A, Ropponen K, Rummukainen J, Kataja V, Kellokoski J, et al. Expression of HER2 and its association with AP-2 in breast cancer. Eur J Cancer 2004, 40:1485-1495. 10.1016/j.ejca.2004.02.020, 15196531.
26. Wajapeyee N, Raut CG, Somasundaram K. Activator protein 2alpha status determines the chemosensitivity of cancer cells: implications in cancer chemotherapy. Cancer Res 2005, 65:8628-8634. 10.1158/0008-5472.CAN-05-1059, 16204029.
27. Kyriazis AP, Kyriazis AA, McCombs WB, Kereiakes JA. Biological behavior of human malignant tumors grown in the nude mouse. Cancer Res 1981, 41:3995-4000.
28. Kyriazis AA, Kyriazis AP, McCombs WB, Peterson WD. Morphological, biological, and biochemical characteristics of human bladder transitional cell carcinomas grown in tissue culture and in nude mice. Cancer Res 1984, 44:3997-4005.
29. Zeng YX, Somasundaram K, el-Deiry WS. AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression. Nat Genet 1997, 15:78-82. 10.1038/ng0197-78, 8988173.
30. Modugno M, Tagliabue E, Ardini E, Berno V, Galmozzi E, De BM, et al. p53-dependent downregulation of metastasis-associated laminin receptor. Oncogene 2002, 21:7478-7487. 10.1038/sj.onc.1205957, 12386810.
31. Wajapeyee N, Somasundaram K. Cell cycle arrest and apoptosis induction by activator protein 2alpha (AP-2alpha) and the role of p53 and p21WAF1/CIP1 in AP-2alpha-mediated growth inhibition. J Biol Chem 2003, 278:52093-52101. 10.1074/jbc.M305624200, 14551210.
32. Orso F, Penna E, Cimino D, Astanina E, Maione F, Valdembri D, et al. AP-2alpha and AP-2gamma regulate tumor progression via specific genetic programs. FASEB J 2008, 22:2702-2714. 10.1096/fj.08-106492, 18443366.
33. Mohamed S, Yasufuku K, Nakajima T, Hiroshima K, Kubo R, Iyoda A, et al. Analysis of cell cycle-related proteins in mediastinal lymph nodes of patients with N2-NSCLC obtained by EBUS-TBNA: relevance to chemotherapy response. Thorax 2008, 63:642-647. 10.1136/thx.2007.090324, 18390633.
34. Karamitopoulou E, Zlobec I, Patsouris E, Peros G, Lugli A. Loss of E-cadherin independently predicts the lymph node status in colorectal cancer. Pathology 2011, 43:133-137. 10.1097/PAT.0b013e3283425b7f, 21233674.
35. Schwartz B, Melnikova VO, Tellez C, Mourad-Zeidan A, Blehm K, Zhao YJ, et al. Loss of AP-2alpha results in deregulation of E-cadherin and MMP-9 and an increase in tumorigenicity of colon cancer cells in vivo. Oncogene 2007, 26:4049-4058. 10.1038/sj.onc.1210193, 17224907.
36. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 2009, 69:5820-5828. 10.1158/0008-5472.CAN-08-2819, 19584296.